

Epigenetic Regulation of Embryonic Development: Insights into Congenital Anomalies

Gul Afshan, Muhammad Muneeb Ather, Waqas Iqbal, Muhammad Shakil Sadiq, Ahmad Farzad Qureshi, Asim mehmood, Farah Naz Tahir

Assistant Professor anatomy

FJMU

gul.afshan@hotmail.com

Assistant Professor Anatomy Shalamar Medical & Dental College, Lahore

drmuneebathar@gmail.com

Associate Professor of Anatomy Sharif Medical and Dental College, Lahore

drwaqasiqbal@gmail.com

Associate Professor of Anatomy Poonch Medical College Rawalakot, AJK

mshakilsadiq@yahoo.com

Associate professor Anatomy Sahiwal medical college

afarzad2001@gmail.com

Associate professor Anatomy. Suleman roshan medical college tandoadam

asimmehmood886@gmail.com

Associate Professor of Biochemistry, Central Park Medical College, Lahore Pakistan,

tahirnazfarah@gmail.com

Abstract

Epigenetic mechanisms are pivotal in orchestrating embryonic development, and their dysregulation has been implicated in the etiology of congenital anomalies. This experimental study aimed to elucidate the role of DNA methylation and histone modification patterns in embryonic tissues associated with congenital malformations. Embryonic samples from 60 cases with diagnosed congenital anomalies and 60 matched controls were analyzed using bisulfite sequencing and chromatin immunoprecipitation assays to assess methylation status and histone modification profiles. Results demonstrated statistically significant hypermethylation at promoter regions of key developmental genes, including HOXA5 and PAX6, in affected samples compared to controls ($p < 0.01$). Additionally, aberrant histone H3K27me3 enrichment was observed in regions critical for neural and cardiac development ($p < 0.05$). These epigenetic alterations correlated with downregulated gene expression levels, confirmed via qRT-PCR. The findings suggest that specific epigenetic modifications contribute to the pathogenesis of congenital anomalies by disrupting gene expression during critical developmental windows. This study provides novel insights into the

epigenetic landscape of embryonic development and underscores potential biomarkers for early detection and therapeutic targets.

Keywords: Epigenetics, Congenital Anomalies, Embryonic Development

Introduction

Embryonic development is a highly regulated process involving precise temporal and spatial gene expression patterns. Epigenetic modifications, including DNA methylation and histone modifications, play a crucial role in regulating gene expression without altering the underlying DNA sequence. These modifications ensure proper cell differentiation and organogenesis. Disruptions in epigenetic regulation can lead to aberrant gene expression, resulting in developmental anomalies and congenital defects.¹⁻³

Recent studies have highlighted the significance of epigenetic mechanisms in embryogenesis. For instance, DNA methylation patterns are established and maintained by DNA methyltransferases (DNMTs), which are essential for normal development. Mutations or altered expression of DNMTs have been associated with various developmental disorders. Similarly, histone modifications, such as methylation and acetylation, influence chromatin structure and gene accessibility, thereby affecting gene transcription during development.⁴⁻⁶

The role of epigenetics in congenital anomalies has garnered increasing attention. Aberrant epigenetic modifications have been implicated in neural tube defects, congenital heart diseases, and craniofacial malformations. Environmental factors, such as maternal nutrition and exposure to toxins, can also influence the epigenetic landscape of the developing embryo, further contributing to the risk of congenital anomalies.⁷⁻⁸

Despite the growing body of evidence linking epigenetic dysregulation to developmental defects, the specific epigenetic alterations associated with various congenital anomalies remain inadequately characterized. Understanding these modifications is essential for developing diagnostic markers and therapeutic interventions aimed at preventing or mitigating congenital defects.⁹⁻¹⁰

This study aims to investigate the epigenetic profiles of embryonic tissues from cases with congenital anomalies compared to matched controls. By analyzing DNA methylation and histone modification patterns, the research seeks to identify specific epigenetic changes associated with developmental defects. The findings are expected to enhance our understanding of the epigenetic underpinnings of congenital anomalies and contribute to the development of targeted strategies for early detection and prevention.

Methodology

A case-control study was conducted at FJMU involving embryonic tissue samples from 60 cases with diagnosed congenital anomalies and 60 matched controls without anomalies. The sample size was calculated using Epi Info software, considering a 95% confidence level, 80% power, and an expected difference in methylation levels of 20% between groups. Inclusion criteria encompassed embryonic tissues obtained from elective terminations between 8 to 12 weeks of gestation, with confirmed diagnoses of congenital anomalies for cases and no detected anomalies for controls. Exclusion criteria included maternal history of chronic illnesses, exposure to known teratogens, or chromosomal abnormalities in the fetus.

Verbal informed consent was obtained from all participants prior to sample collection, in accordance with ethical guidelines. DNA was extracted from embryonic tissues using standard phenol-chloroform methods. Bisulfite sequencing was performed to assess DNA methylation patterns at promoter regions of developmental genes. Chromatin immunoprecipitation (ChIP) assays were conducted using antibodies specific to histone modifications, particularly H3K27me3, to evaluate histone modification profiles. Quantitative real-time PCR (qRT-PCR) was utilized to measure gene expression levels of target genes.

Statistical analyses were performed using SPSS software. Mean methylation levels and histone modification enrichment were compared between cases and controls using independent t-tests. Correlations between epigenetic modifications and gene expression levels were assessed using Pearson correlation coefficients. A p-value of less than 0.05 was considered statistically significant.

Results

Table 1: Demographic Characteristics of Study Participants

Characteristic	Cases (n=60)	Controls (n=60)	p-value
Maternal Age (years)	28.5 ± 4.2	27.9 ± 3.8	0.45
Gestational Age (weeks)	10.2 ± 1.1	10.1 ± 1.0	0.60
Maternal BMI (kg/m²)	24.3 ± 2.5	23.8 ± 2.3	0.30

Note: No significant differences were observed in demographic characteristics between cases and controls.

Table 2: DNA Methylation Levels at Promoter Regions of Developmental Genes

Gene	Cases (%)	Controls (%)	p-value
HOXA5	65.2 ± 5.1	45.3 ± 4.8	<0.001
PAX6	70.1 ± 6.0	50.5 ± 5.5	<0.001
SOX2	60.4 ± 5.7	42.2 ± 4.9	<0.001

Note: Significant hypermethylation was observed at promoter regions of HOXA5, PAX6, and SOX2 in cases compared to controls.

Table 3: Histone H3K27me3 Enrichment at Developmental Gene Loci

Gene	Cases (Fold Enrichment)	Controls (Fold Enrichment)	p-value
NKX2.5	2.8 ± 0.3	1.5 ± 0.2	<0.001
GATA4	3.2 ± 0.4	1.7 ± 0.3	<0.001
TBX5	2.5 ± 0.3	1.4 ± 0.2	<0.001

Note: Increased H3K27me3 enrichment at NKX2.5, GATA4, and TBX5 loci was observed in cases, indicating repressive chromatin states.

Discussion

The findings of this study underscore the pivotal role of epigenetic modifications, specifically DNA methylation and histone modifications, in the etiology of congenital anomalies. The observed hypermethylation at promoter regions of developmental genes such as HOXA5, PAX6, and SOX2 aligns with previous research indicating that aberrant DNA methylation patterns can disrupt normal gene expression during embryogenesis. These epigenetic alterations may lead to the silencing of critical genes necessary for proper organ development, thereby contributing to the manifestation of congenital defects.¹¹⁻¹³

Furthermore, the increased enrichment of the repressive histone mark H3K27me3 at loci of key cardiac developmental genes (NKX2.5, GATA4, and TBX5) suggests a mechanism by which histone modifications can influence gene expression patterns during heart development. This is consistent with studies demonstrating that histone modifications play a crucial role in regulating gene expression during embryonic development and that disruptions in these modifications can lead to congenital heart defects.¹⁴⁻¹⁶

The correlation between these epigenetic changes and downregulated gene expression, as confirmed by qRT-PCR, highlights the functional impact of these modifications on gene activity. This supports the hypothesis that epigenetic dysregulation can lead to altered gene expression profiles, ultimately resulting in developmental anomalies.¹⁷⁻²⁰

Moreover, the findings of this study contribute to the growing body of evidence that environmental factors, such as maternal health and exposure to toxins, can influence the epigenetic landscape of the developing embryo. This is particularly relevant in the context of maternal diabetes, where studies have shown that hyperglycemia can lead to epigenetic alterations in embryonic tissues, thereby increasing the risk of congenital anomalies.²¹⁻²³

The identification of specific epigenetic signatures associated with congenital anomalies has significant implications for early diagnosis and potential therapeutic interventions. By understanding the epigenetic mechanisms underlying these defects, it may be possible to develop targeted strategies to prevent or mitigate their occurrence. For instance, interventions aimed at modulating DNA methylation patterns or histone modifications could potentially restore normal gene expression during critical periods of development.²⁴⁻²⁵

In conclusion, this study provides novel insights into the epigenetic regulation of embryonic development and its role in the pathogenesis of congenital anomalies. The findings highlight the importance of epigenetic mechanisms in developmental processes and underscore the need for further research to explore the potential of epigenetic therapies in preventing or treating congenital defects.

Conclusion

This study elucidates the significant role of epigenetic modifications, particularly DNA methylation and histone modifications, in the development of congenital anomalies. By identifying specific epigenetic alterations associated with these defects, the research fills a critical gap in understanding the molecular mechanisms underlying developmental disorders. Future studies should focus on exploring the therapeutic potential of modulating epigenetic marks to prevent or treat congenital anomalies.

References

1. Xie, Z. et al. Metabolic regulation of gene expression by histone lysine β -hydroxybutyrylation. *Mol. Cell* **62**, 194–206 (2016).
2. Moazzen, H. et al. N-Acetylcysteine prevents congenital heart defects induced by pregestational diabetes. *Cardiovasc. Diabetol.* **13**, 46 (2014).
3. Yang, P. et al. Maternal hyperglycemia activates an ASK1–FoxO3a–caspase 8 pathway that leads to embryonic neural tube defects. *Sci. Signal.* **6**, ra74 (2013).
4. Hrubec, T. C., Prater, M. R., Toops, K. A. & Holladay, S. D. Reduction in diabetes-induced craniofacial defects by maternal immune stimulation. *Birth Defects Res. B* **77**, 1–9 (2006).
5. Hao, Y. et al. Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587.e3529 (2021).
6. Granja, J. M. et al. ArchR is a scalable software package for integrative single-cell chromatin accessibility analysis. *Nat. Genet.* **53**, 403–411 (2021).
7. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell* **38**, 576–589 (2010).

8. Simoes-Costa, M. & Bronner, M. E. Establishing neural crest identity: a gene regulatory recipe. *Development* **142**, 242–257 (2015).
9. Parker, H. J., Pushel, I. & Krumlauf, R. Coupling the roles of Hox genes to regulatory networks patterning cranial neural crest. *Dev. Biol.* **444**, S67–S78 (2018).
10. Dooley, C. M. et al. The gene regulatory basis of genetic compensation during neural crest induction. *PLoS Genet.* **15**, e1008213 (2019).
11. Rothstein, M. & Simoes-Costa, M. Heterodimerization of TFAP2 pioneer factors drives epigenomic remodeling during neural crest specification. *Genome Res.* **30**, 35–48 (2020).
12. Fan, X. et al. TWIST1 and chromatin regulatory proteins interact to guide neural crest cell differentiation. *eLife* <https://doi.org/10.7554/eLife.62873> (2021).
13. Soldatov, R. et al. Spatiotemporal structure of cell fate decisions in murine neural crest. *Science* <https://doi.org/10.1126/science.aas9536> (2019).
14. Akerberg, B. N. et al. A reference map of murine cardiac transcription factor chromatin occupancy identifies dynamic and conserved enhancers. *Nat. Commun.* **10**, 4907 (2019).
15. Prall, O. W. et al. An Nkx2-5/Bmp2/Smad1 negative feedback loop controls heart progenitor specification and proliferation. *Cell* **128**, 947–959 (2007).
16. Schussler, O. et al. Cardiac neural crest cells: their rhombomeric specification, migration, and association with heart and great vessel anomalies. *Cell Mol. Neurobiol.* **41**, 403–429 (2021).
17. Rada-Iglesias, A. et al. Epigenomic annotation of enhancers predicts transcriptional regulators of human neural crest. *Cell Stem Cell* **11**, 633–648 (2012).
18. Maconochie, M. et al. Regulation of Hoxa2 in cranial neural crest cells involves members of the AP-2 family. *Development* **126**, 1483–1494 (1999).
19. Kutejova, E., Engist, B., Mallo, M., Kanzler, B. & Bobola, N. Hoxa2 downregulates Six2 in the neural crest-derived mesenchyme. *Development* **132**, 469–478 (2005).
20. Van Otterloo, E., Li, H., Jones, K. L. & Williams, T. AP-2 α and AP-2 β cooperatively orchestrate homeobox gene expression during branchial arch patterning. *Development* **145**, dev157438 (2018).
21. Kirilenko, P. et al. Transient activation of meox1 is an early component of the gene regulatory network downstream of hoxa2. *Mol. Cell. Biol.* **31**, 1301–1308 (2011).

22. Alexanian, M. et al. A transcriptional switch governs fibroblast activation in heart disease. *Nature* **595**, 438–443 (2021).
23. Kruzynska-Frejtag, A. et al. Periostin is expressed within the developing teeth at the sites of epithelial–mesenchymal interaction. *Dev. Dyn.* **229**, 857–868 (2004).
24. Verzi, M. P., McCulley, D. J., De Val, S., Dodou, E. & Black, B. L. The right ventricle, outflow tract, and ventricular septum comprise a restricted expression domain within the secondary/anterior heart field. *Dev. Biol.* **287**, 134–145 (2005).